Lifecore Biomedical, Inc. \de\ SEC filings LFCR
Lifecore Biomedical, Inc. \de\ has 1,005 filings in SEC EDGAR's recent list, going back to May 16, 2012. Its latest annual report, Form 10-KT, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on May 25.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2025 | — |
| EFFECT | Filing | Oct 22, 2024 | — |
| CORRESP | Letter to the SEC | Oct 18, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 18, 2024 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| NT 10-K | Filing | Aug 12, 2024 | May 26, 2024 |
| UPLOAD | Letter from the SEC | Jun 13, 2024 | — |
| CORRESP | Letter to the SEC | Jun 7, 2024 | — |
| UPLOAD | Letter from the SEC | May 13, 2024 | — |
| NT 10-Q | Filing | Apr 8, 2024 | Feb 25, 2024 |
| NT 10-Q | Filing | Jan 10, 2024 | Nov 26, 2023 |
| NT 10-Q | Filing | Oct 10, 2023 | Aug 27, 2023 |
| NT 10-K | Filing | Aug 14, 2023 | May 28, 2023 |
| EFFECT | Filing | Jun 9, 2023 | — |
| CORRESP | Letter to the SEC | Jun 7, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2023 | — |
| NT 10-Q | Filing | Apr 10, 2023 | Feb 26, 2023 |
| NT 10-Q | Filing | Jan 9, 2023 | Nov 27, 2022 |
| NT 10-K | Filing | Aug 15, 2022 | Aug 15, 2022 |
| UPLOAD | Letter from the SEC | Mar 10, 2021 | — |
| CORRESP | Letter to the SEC | Mar 8, 2021 | — |
| CORRESP | Letter to the SEC | Feb 16, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2021 | — |
| NT 10-Q | Form nt 10-q | Jan 7, 2019 | Nov 25, 2018 |
| D | Filing | Dec 6, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2018 | — |
| CORRESP | Letter to the SEC | Mar 14, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 16, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 15, 2017 | — |
| CORRESP | Letter to the SEC | Feb 7, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2017 | — |
| EFFECT | Filing | Nov 2, 2015 | — |
| CORRESP | Letter to the SEC | Oct 27, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2014 | — |
| CORRESP | Letter to the SEC | Mar 5, 2014 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2014 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFCR (Nasdaq)
- Fiscal year ends
- May 25
- Incorporated in
- DE
- Headquarters
- Chaska, MN
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1005286
- Former names
- LANDEC CORP \CA\ (until Nov 7, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.